The number and effects of mutations leading to full drug resistance crucially determine treatment failure probability and should be used to inform antimicrobial treatment strategies with regard to avoidance of resistance emergence.

Biological and pharmacokinetic studies indicate that the anti-tubercular drug, delamanid, could be repurposed for the treatment of visceral leishmaniasis.

GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.

Most chloroquine regimens trialled for the treatment of COVID19 will not result in life-threatening cardiovascular toxicity.

A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.

Erastin and sorafenib inhibit system x_c^- and induce ER stress, suggesting these may be useful tools for probing the functions of system x_c^- and its role in inducing ER stress and ferroptosis.

The first-in-class, humanized, epitope-specific FSH-blocking antibody MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for further development towards future testing in human trials for osteoporosis, obesity, dyslipidemia and neurodegeneration.

The DLK response pathway in neurons initiates the cascade of events leading to neuropathic pain after injury.

Live-cell imaging captures the heterogenity of bacterial growth within intracellular bacterial communities and demonstrates that the constituent bacteria are protected from clearance by antibiotics delivered with a physiologically relevant pharmacodynamic profile.

A mathematical model of blood-stage infection with Plasmodium falciparum malaria capturing the sexual stage of the parasite life-cycle is validated against human data, providing new insight into human-to-mosquito transmission.